Myfembree Support Program News Today

Pfizer And Myovant Get FDA Nod For Myfembree NEW YORK CITY (dpa-AFX) - Pfizer Inc. and Myovant Sciences announced that the U.S. Food and Drug Administration has approved Myfembree, the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids. Under the collaboration terms, Myovant and Pfizer will jointly commercialize Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) in the U.S. The drug is expected to be available in June 2021. Myfemb...